Wall Street analysts expect AxoGen, Inc Common Stock (NASDAQ:AXGN) to report earnings per share (EPS) of ($0.05) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for AxoGen, Inc Common Stock’s earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.01). AxoGen, Inc Common Stock reported earnings of ($0.06) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 16.7%. The firm is expected to report its next earnings results on Wednesday, November 7th.

On average, analysts expect that AxoGen, Inc Common Stock will report full year earnings of ($0.27) per share for the current financial year, with EPS estimates ranging from ($0.31) to ($0.22). For the next fiscal year, analysts forecast that the company will post earnings of ($0.11) per share, with EPS estimates ranging from ($0.16) to ($0.07). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover AxoGen, Inc Common Stock.

AxoGen, Inc Common Stock (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01). AxoGen, Inc Common Stock had a negative net margin of 24.96% and a negative return on equity of 26.50%. The company had revenue of $20.58 million for the quarter, compared to analysts’ expectations of $21.25 million. During the same quarter in the previous year, the company posted ($0.04) EPS. The business’s quarterly revenue was up 35.7% on a year-over-year basis.

Several equities analysts have commented on AXGN shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $45.00 price objective on shares of AxoGen, Inc Common Stock in a research report on Thursday, August 9th. ValuEngine raised AxoGen, Inc Common Stock from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Leerink Swann reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of AxoGen, Inc Common Stock in a research report on Tuesday, June 26th. BidaskClub downgraded AxoGen, Inc Common Stock from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. Finally, JMP Securities upped their price objective on AxoGen, Inc Common Stock from $34.00 to $43.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 1st. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $41.29.

In other AxoGen, Inc Common Stock news, Director Amy Mcbride Wendell acquired 5,000 shares of the business’s stock in a transaction on Tuesday, August 14th. The shares were bought at an average price of $36.89 per share, with a total value of $184,450.00. Following the transaction, the director now directly owns 18,333 shares of the company’s stock, valued at approximately $676,304.37. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 7.86% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers grew its position in shares of AxoGen, Inc Common Stock by 5.5% during the 1st quarter. Rhumbline Advisers now owns 25,538 shares of the medical equipment provider’s stock worth $932,000 after buying an additional 1,335 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in shares of AxoGen, Inc Common Stock by 41.6% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,575 shares of the medical equipment provider’s stock worth $167,000 after buying an additional 1,345 shares in the last quarter. Metropolitan Life Insurance Co. NY grew its position in shares of AxoGen, Inc Common Stock by 16.9% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 10,929 shares of the medical equipment provider’s stock worth $549,000 after buying an additional 1,579 shares in the last quarter. Northern Trust Corp grew its position in shares of AxoGen, Inc Common Stock by 0.5% during the 1st quarter. Northern Trust Corp now owns 332,844 shares of the medical equipment provider’s stock worth $12,149,000 after buying an additional 1,649 shares in the last quarter. Finally, Financial Architects Inc grew its position in shares of AxoGen, Inc Common Stock by 29.6% during the 2nd quarter. Financial Architects Inc now owns 7,391 shares of the medical equipment provider’s stock worth $371,000 after buying an additional 1,686 shares in the last quarter. 71.18% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:AXGN opened at $37.75 on Wednesday. The firm has a market cap of $1.47 billion, a P/E ratio of -118.71 and a beta of 0.01. AxoGen, Inc Common Stock has a fifty-two week low of $15.10 and a fifty-two week high of $56.85.

About AxoGen, Inc Common Stock

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Further Reading: Relative Strength Index

Get a free copy of the Zacks research report on AxoGen, Inc Common Stock (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen, Inc Common Stock (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.